BGMS
NASDAQ · Biotechnology
Bio Green Med Solution Inc
$1.01
+0.01 (+1.00%)
BGMS News10 articles
Biogen Acquires Apellis in $5.6B Deal, Adding Eye and Kidney Drugs
Biogen has entered a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion. The deal includes a $41 per share cash offer plus contingent value rights.
Biogen to Acquire Apellis in $5.6B Deal, Adding Rare Disease Portfolio
Biogen has entered an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash. The deal provides Apellis shareholders $41 per share upfront, with potential additional payments based on sales performance of the eye drug Syfovre.
ImmunityBio Surges on NK-Cell Manufacturing Milestone, Anktiva Expansion Progress
ImmunityBio shares jumped 10.5% Friday following news of a completed scalable manufacturing process for its NK-cell therapy platform and regulatory progress for its drug Anktiva. The company also reported surging 2025 revenue.
Atara Biotherapeutics Surges on FDA Leadership Shift, EBVALLO Review in Focus
Atara Biotherapeutics shares surged 18% Monday following news of an upcoming FDA leadership change, reviving investor hope for a reconsideration of its rejected EBVALLO therapy for a rare blood cancer.
Servier Acquires Day One Biopharmaceuticals in $2.5 Billion Oncology Deal
French pharmaceutical firm Servier will acquire Day One Biopharmaceuticals for $2.5 billion, gaining the pediatric glioma treatment Ojemda. The deal offers a 68% premium to Day One's recent closing price.
ImmunityBio Shares Dip Ahead of Key Business Update Call
ImmunityBio shares edged lower in premarket activity Tuesday, giving back some of the prior session's gains ahead of a scheduled business update and full-year results call later in the day.
BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO and targets a late-2027 regulatory submission.
BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell nearly 3% in premarket trading following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO.
BioCryst Shares Slip on New Hereditary Angioedema Drug Data
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company reaffirmed its 2026 revenue outlook and plans a Phase 3 filing by late 2027.
ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.